Tvardi's TTI-101 breast cancer trial posts results after early terminationTrial updateTTI-101Tvardi Therapeutics, Incorporated
Quarterly updateTvardi Therapeutics, IncorporatedTvardi reports healthy volunteer data for TTI-109, picks ulcerative colitis as lead indicationThe company said topline results confirmed the prodrug design of its next-generation STAT3 inhibitor and plans an IND-enabled UC trial start in 2027.SEC filing
Regulatory decisionTvardi Therapeutics, IncorporatedTvardi selects ulcerative colitis as first indication for TTI-109, sets KOL webinarThe company cites Phase 1 immune cell data and unveils plans for a 2027 UC trial, with an August 19 webinar featuring Dr. Randy Longman.SEC filing
FinancingTvardi Therapeutics, IncorporatedTvardi Therapeutics files for up to $9.7 million more in at-the-market stock salesThe Nasdaq-listed biopharma registered a new prospectus supplement covering additional stock sales through JonesTrading after selling $11 million under a prior agreement.SEC filing
